Investment case
Enhabit Home Health & Hospice
EHRT · 2 developments mapped · last assessed 2026-09-18
Market Ontology has mapped 2 macro, policy, and market developments to Enhabit Home Health & Hospice since 2026-09-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for EHRT yet, so no modelled value is shown. The EHRT valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run EHRT on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Drop
Indirect impact from reduced Medicaid enrollment potentially leading to lower demand for home health and hospice services for this population.
· Moves patient volume growth, payer mix
- Open question
Centene Streamlines Medicare Advantage Footprint with Q2 Ratio at 89.5%
Potential shifts in referral patterns and utilization management from MA plans focusing on higher-retention, dual-eligible members.
· Moves referral volumes from ma plans, reimbursement rates
What changed, by assumption
- 2026-09-18Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Drop
- 2026-09-12Centene Streamlines Medicare Advantage Footprint with Q2 Ratio at 89.5%
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-18 | Centene Delivers Q2 Adjusted EPS of $2.51, Projects 8%-9% Medicaid Drop | Bearish | 3-12m | 0.30 |
| 2026-09-12 | Centene Streamlines Medicare Advantage Footprint with Q2 Ratio at 89.5% | watch | 3-12m | 0.30 |